Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) was upgraded by equities researchers at Mizuho from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.
Several other research analysts also recently commented on CRVS. StockNews.com raised shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. LADENBURG THALM/SH SH lifted their price objective on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, September 16th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $10.83.
View Our Latest Report on Corvus Pharmaceuticals
Corvus Pharmaceuticals Stock Down 2.5 %
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.05. During the same quarter in the previous year, the company earned ($0.14) earnings per share. Equities research analysts anticipate that Corvus Pharmaceuticals will post -0.45 EPS for the current year.
Institutional Investors Weigh In On Corvus Pharmaceuticals
Several hedge funds have recently bought and sold shares of CRVS. Point72 Asset Management L.P. purchased a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter valued at $10,855,000. Samlyn Capital LLC increased its stake in Corvus Pharmaceuticals by 160.7% in the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock valued at $11,144,000 after acquiring an additional 3,774,658 shares during the last quarter. Vanguard Group Inc. increased its stake in Corvus Pharmaceuticals by 10.6% in the first quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock valued at $2,658,000 after acquiring an additional 142,724 shares during the last quarter. Marshall Wace LLP purchased a new stake in Corvus Pharmaceuticals during the second quarter valued at about $136,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Corvus Pharmaceuticals during the second quarter worth about $44,000. 46.64% of the stock is currently owned by institutional investors.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
See Also
- Five stocks we like better than Corvus Pharmaceuticals
- What is the Euro STOXX 50 Index?
- Monster and Celsius Energized: Which Stock Offers More Upside?
- Buy P&G Now, Before It Sets A New All-Time High
- Sherwin-Williams Plunges Into Buying Opportunity: Time to Buy?
- How to Invest in Blue Chip Stocks
- Wolverine World Wide Breaks Out – Will the 92% Rally Continue?
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.